AB Corporate Bond ETF (NASDAQ:EYEG) Sees Significant Drop in Short Interest

AB Corporate Bond ETF (NASDAQ:EYEG) was the recipient of a significant decline in short interest in the month of August. As of August 14th, there was short interest totaling 78 shares, a decline of 88.1% from the July 30th total of 655 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 861 shares, the days-to-cover ratio is currently 0.1 days.

AB Corporate Bond ETF Stock Performance

Shares of NASDAQ:EYEG traded down $0.02 on Thursday, reaching $34.70. 170 shares of the company’s stock were exchanged, compared to its average volume of 277. AB Corporate Bond ETF has a fifty-two week low of $34.46 and a fifty-two week high of $36.63. The business’s 50-day moving average is $34.83 and its two-hundred day moving average is $35.20. The company has a quick ratio of 3.07, a current ratio of 3.07 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $27.76 million, a price-to-earnings ratio of -20.65 and a beta of 0.18.

AB Corporate Bond ETF Increases Dividend

The business also recently disclosed a monthly dividend, which was paid on Thursday, August 6th. Investors of record on Monday, August 3rd were given a dividend of $0.1427 per share. The ex-dividend date was Monday, August 3rd. This represents a c) dividend on an annualized basis and a yield of 4.9%. This is an increase from AB Corporate Bond ETF’s previous monthly dividend of $0.14. AB Corporate Bond ETF’s payout ratio is presently -102.38%.

Institutional Investors Weigh In On AB Corporate Bond ETF

An institutional investor recently raised its position in AB Corporate Bond ETF stock. Jane Street Group LLC increased its position in AB Corporate Bond ETF (NASDAQ:EYEG) by 166.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,741 shares of the specialty pharmaceutical company’s stock after acquiring an additional 9,839 shares during the period. Jane Street Group LLC owned approximately 2.10% of AB Corporate Bond ETF worth $563,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 64.16% of the company’s stock.

AB Corporate Bond ETF Company Profile

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.